Astrazeneca Plc (NASDAQ: AZN )
Astrazeneca Plc's Customers Performance
AZN
AZN's Source of Revenues
During the corresponding time, Astrazeneca Plc recorded a revenue increase by 8.63 % year on year, While revenue at the Astrazeneca Plc's corporate clients • List of AZN Customers
for the same period Astrazeneca Plc recorded revenue increase by
8.63 % year on year,
• List of AZN Customers
US
of total Revenue
Emerging Markets
of total Revenue
Europe
of total Revenue
Rest of World
of total Revenue
Total Oncology
of total Revenue
Total Oncology US
of total Revenue
Total Oncology Emerging Markets
of total Revenue
Total Oncology Europe
of total Revenue
Total Oncology Rest of World
of total Revenue
Tagrisso
of total Revenue
Tagrisso US
of total Revenue
Tagrisso Emerging Markets
of total Revenue
Tagrisso Europe
of total Revenue
Tagrisso Rest of World
of total Revenue
Imfinzi
of total Revenue
Imfinzi US
of total Revenue
Imfinzi Emerging Markets
of total Revenue
Imfinzi Europe
of total Revenue
Imfinzi Rest of World
of total Revenue
Calquence
of total Revenue
Calquence US
of total Revenue
Calquence Emerging Markets
of total Revenue
Calquence Europe
of total Revenue
Calquence Rest of World
of total Revenue
Lynparza
of total Revenue
Lynparza US
of total Revenue
Lynparza Emerging Markets
of total Revenue
Lynparza Europe
of total Revenue
Lynparza Rest of World
of total Revenue
Enhertu
of total Revenue
Enhertu Emerging Markets
of total Revenue
Enhertu Europe
of total Revenue
Enhertu Rest of World
of total Revenue
Zoladex
of total Revenue
Zoladex US
of total Revenue
Zoladex Emerging Markets
of total Revenue
Zoladex Europe
of total Revenue
Zoladex Rest of World
of total Revenue
Truqap
of total Revenue
Truqap US
of total Revenue
Truqap Emerging Markets
of total Revenue
Truqap Europe
of total Revenue
Truqap Rest of World
of total Revenue
Imjudo
of total Revenue
Imjudo US
of total Revenue
Imjudo Emerging Markets
of total Revenue
Imjudo Europe
of total Revenue
Imjudo Rest of World
of total Revenue
Datroway
of total Revenue
Datroway Emerging Markets
of total Revenue
Oncology Others
of total Revenue
Oncology Others US
of total Revenue
Oncology Others Emerging Markets
of total Revenue
Oncology Others Europe
of total Revenue
Oncology Others Rest of World
of total Revenue
CVRM
of total Revenue
CVRM US
of total Revenue
CVRM Emerging Markets
of total Revenue
CVRM Europe
of total Revenue
CVRM Rest of World
of total Revenue
Farxiga
of total Revenue
Farxiga US
of total Revenue
Farxiga Emerging Markets
of total Revenue
Farxiga Europe
of total Revenue
Farxiga Rest of World
of total Revenue
Crestor
of total Revenue
Crestor US
of total Revenue
Crestor Emerging Markets
of total Revenue
Crestor Europe
of total Revenue
Crestor Rest of World
of total Revenue
Brilinta
of total Revenue
Brilinta US
of total Revenue
Brilinta Emerging Markets
of total Revenue
Brilinta Europe
of total Revenue
Brilinta Rest of World
of total Revenue
Lokelma
of total Revenue
Lokelma US
of total Revenue
Lokelma Emerging Markets
of total Revenue
Lokelma Europe
of total Revenue
Lokelma Rest of World
of total Revenue
Seloken
of total Revenue
Seloken Emerging Markets
of total Revenue
Seloken Europe
of total Revenue
Seloken Rest of World
of total Revenue
Roxadustat
of total Revenue
Roxadustat Emerging Markets
of total Revenue
Wainua
of total Revenue
Wainua US
of total Revenue
Wainua Emerging Markets
of total Revenue
Wainua Europe
of total Revenue
CVRM Others
of total Revenue
CVRM Others US
of total Revenue
CVRM Others Emerging Markets
of total Revenue
CVRM Others Europe
of total Revenue
CVRM Others Rest of World
of total Revenue
Total Respiratory Immunology
of total Revenue
Total Respiratory Immunology US
of total Revenue
Total Respiratory Immunology Emerging Markets
of total Revenue
Total Respiratory Immunology Europe
of total Revenue
Total Respiratory Immunology Rest of World
of total Revenue
Symbicort
of total Revenue
Symbicort US
of total Revenue
Symbicort Emerging Markets
of total Revenue
Symbicort Europe
of total Revenue
Symbicort Rest of World
of total Revenue
Fasenra
of total Revenue
Fasenra US
of total Revenue
Fasenra Emerging Markets
of total Revenue
Fasenra Europe
of total Revenue
Fasenra Rest of World
of total Revenue
Breztri
of total Revenue
Breztri US
of total Revenue
Breztri Emerging Markets
of total Revenue
Breztri Europe
of total Revenue
Breztri Rest of World
of total Revenue
Tezspire
of total Revenue
Tezspire Emerging Markets
of total Revenue
Tezspire Europe
of total Revenue
Tezspire Rest of World
of total Revenue
Saphnelo
of total Revenue
Saphnelo US
of total Revenue
Saphnelo Emerging Markets
of total Revenue
Saphnelo Europe
of total Revenue
Saphnelo Rest of World
of total Revenue
Pulmicort
of total Revenue
Pulmicort US
of total Revenue
Pulmicort Emerging Markets
of total Revenue
Pulmicort Europe
of total Revenue
Pulmicort Rest of World
of total Revenue
Airsupra
of total Revenue
Airsupra US
of total Revenue
Airsupra Emerging Markets
of total Revenue
Respiratory and immunology Others
of total Revenue
Respiratory and immunology Others US
of total Revenue
Respiratory and immunology Others Emerging Markets
of total Revenue
Respiratory and immunology Others Europe
of total Revenue
Respiratory and immunology Others Rest of World
of total Revenue
Vaccines Immune Therapies
of total Revenue
Vaccines Immune Therapies US
of total Revenue
Vaccines Immune Therapies Emerging Markets
of total Revenue
Vaccines Immune Therapies Europe
of total Revenue
Vaccines Immune Therapies Rest of World
of total Revenue
Beyfortus
of total Revenue
Beyfortus US
of total Revenue
Beyfortus Europe
of total Revenue
Beyfortus Rest of World
of total Revenue
Synagis
of total Revenue
Synagis US
of total Revenue
Synagis Emerging Markets
of total Revenue
Synagis Europe
of total Revenue
Synagis Rest of World
of total Revenue
FluMist
of total Revenue
FluMist US
of total Revenue
FluMist Emerging Markets
of total Revenue
FluMist Europe
of total Revenue
FluMist Rest of World
of total Revenue
Vaccines Immune Therapies Others
of total Revenue
Vaccines Immune Therapies Others Emerging Markets
of total Revenue
Total Rare Disease
of total Revenue
Total Rare Disease US
of total Revenue
Total Rare Disease Emerging Markets
of total Revenue
Total Rare Disease Europe
of total Revenue
Total Rare Disease Rest of World
of total Revenue
Ultomiris
of total Revenue
Ultomiris US
of total Revenue
Ultomiris Emerging Markets
of total Revenue
Ultomiris Europe
of total Revenue
Ultomiris Rest of World
of total Revenue
Soliris
of total Revenue
Soliris US
of total Revenue
Soliris Emerging Markets
of total Revenue
Soliris Europe
of total Revenue
Soliris Rest of World
of total Revenue
Strensiq
of total Revenue
Strensiq US
of total Revenue
Strensiq Emerging Markets
of total Revenue
Strensiq Europe
of total Revenue
Strensiq Rest of World
of total Revenue
Koselugo
of total Revenue
Koselugo US
of total Revenue
Koselugo Emerging Markets
of total Revenue
Koselugo Europe
of total Revenue
Koselugo Rest of World
of total Revenue
Rare Disease Others
of total Revenue
Rare Disease Others US
of total Revenue
Rare Disease Others Emerging Markets
of total Revenue
Rare Disease Others Europe
of total Revenue
Rare Disease Others Rest of World
of total Revenue
Total Other medicines
of total Revenue
Total Other medicines US
of total Revenue
Total Other medicines Emerging Markets
of total Revenue
Total Other medicines Europe
of total Revenue
Total Other medicines Rest of World
of total Revenue
Nexium
of total Revenue
Nexium US
of total Revenue
Nexium Emerging Markets
of total Revenue
Nexium Europe
of total Revenue
Nexium Rest of World
of total Revenue
Other Others
of total Revenue
Other Others US
of total Revenue
Other Others Emerging Markets
of total Revenue
Other Others Europe
of total Revenue
Other Others Rest of World
of total Revenue
Other royalty income
of total Revenue
Other Alliance Revenue
of total Revenue
Farxiga sales milestones
of total Revenue
Other Collaboration Revenue
of total Revenue
UNITED KINGDOM
of total Revenue
Outside the UK
of total Revenue
Rest of Europe
of total Revenue
FRANCE
of total Revenue
GERMANY
of total Revenue
ITALY
of total Revenue
SPAIN
of total Revenue
SWEDEN
of total Revenue
Others Europe
of total Revenue
The Americas
of total Revenue
CANADA
of total Revenue
Other Americas excluding US and Canada
of total Revenue
Asia Africa And Australasia
of total Revenue
AUSTRALIA
of total Revenue
CHINA
of total Revenue
JAPAN
of total Revenue
Other Asia Africa and Australasia excluding Australia China and Japan
of total Revenue
Customer one
of total Revenue
Customer two
of total Revenue
Select the Relationship:
Select the Category:
Astrazeneca Plc's Comment on Sales, Marketing and Customers
The company supplies products to industry OEMs, tier one suppliers, distributors, and the U.S. Government across Transportation, Industrial, Medical, and Aerospace and Defense sectors. Its major product categories are SENSE (including controls, pedals, piezo sensing products, sensors, switches, and transducers), CONNECT (including EMI/RFI filters, capacitors, frequency control products, resistors, and RF filters), and MOVE (including piezo microactuators and rotary actuators). In 2025, net sales by end market were 43% Transportation, 26% Industrial, 16% Medical, and 15% Aerospace and Defense. Sales and marketing are conducted through sales engineers, independent manufacturers' representatives, and distributors. Sales engineers accounted for approximately 86% of 2025 net sales, distributors about 7%, and independent manufacturers' representatives approximately 7%. Distributors primarily serve smaller customers and provide supply chain fulfillment. Key distribution partners include Avnet, Inc., Digi-Key Electronics, Master Electronics, Future Electronics, and TTI, Inc.
Astrazeneca Plc’s Comment on Sales, Marketing and Customers
AZN's vs. Customers, Data
(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)
COMPANY NAME
MARKET CAP
REVENUES
INCOME
EMPLOYEES
Astrazeneca Plc
263,696.84
58,739.00
10,233.00
83,100
Allarity Therapeutics Inc
13.93
23.79
-12.33
8
Avnet Inc
7,595.77
27,630.24
334.39
15,040
Ionis Pharmaceuticals Inc
7,510.02
1,169.42
-313.02
1,402
Ironwood Pharmaceuticals inc
606.86
389.32
129.87
100
Tetra Technologies Inc
753.72
609.68
6.20
1,400
SUBTOTAL
102,294.16
64,716.89
2,706.53
36,100
1 more clients available
Sign in to see all corporate customers for Astrazeneca Plc.
Sources:
Astrazeneca Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, October 17, 2026 5:39 AM
9 tables on Astrazeneca Plc corporate clients.
Customers & Markets .
40.81 %